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 The IL-1RI co-receptor, TILRR, is a potent
ampliﬁer of IL-1–induced responses.
 Blocking TILRR inhibits IL-1 receptor
function and activation of inﬂammatory
genes.
 TILRR expression is high in
atherosclerotic lesions but low in healthy
tissue, allowing distinct inhibition at sites
of inﬂammation.
 Genetic deletion of TILRR and antibody
blocking of TILRR function reduce plaque
development and progression of
atherosclerosis. Lesions exhibit low levels
of macrophages and increased levels of
smooth muscle cells and collagen,
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ABBAND ACRONYMS
ApoE = apolipoprotein E
DK = double knockout
GAPDH = glyceraldehyde
3-phosphate dehydrogenase
iBALT = inducible bronchus-
associated lymphoid tissue
IgG = immunoglobulin G
IkBa = inhibitor kappa B alpha
IL = interleukin
IL-1RI = interleukin-1 receptorExpression of the interleukin-1 receptor type I (IL-1RI) co-receptor Toll-like and interleukin-1 receptor regu-
lator (TILRR) is signiﬁcantly increased in blood monocytes following myocardial infarction and in the atherosclerotic
plaque, whereas levels in healthy tissue are low. TILRR association with IL-1RI at these sites causes aberrant acti-
vation of inﬂammatory genes, which underlie progression of cardiovascular disease. The authors show that genetic
deletion of TILRR or antibody blocking of TILRR function reduces development of atherosclerotic plaques. Lesions
exhibit decreased levels of monocytes, with increases in collagen and smooth muscle cells, characteristic features of
stable plaques. The results suggest that TILRRmay constitute a rational target for site- and signal-speciﬁc inhibition of
vasculardisease. (JAmCollCardiol Basic TransScience2017;2:398–414)©2017 The Authors. PublishedbyElsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY 4.0
license (http://creativecommons.org/licenses/by/4.0/).
ItypeKO = knockout
LDLR–/– = low-density
lipoprotein receptor–/–
LPS = lipopolysaccharide
NF-kB = nuclear factor-kappa B
NSTEMI = non–ST-segment
elevation myocardial infarction
PBS = phosphate-buffered
saline
PCR = polymerase chain
reaction
qPCR = quantitativeR eceptors of the toll-like and interleukin (IL)-1family are central to control of immunity andinﬂammation, and their importance in dis-
ease is well documented (1–4). Activation is induced
by ligand binding and by association of system-
speciﬁc co-receptors, which regulate signal ampliﬁca-
tion and transcriptional activity (1,4,5). Changes in
co-receptor expression and causative mutations
impact responses to infection, tissue damage and
stress, and affect development of disease (5).SEE PAGE 415
polymerase chain reaction
SDS = sodium dodecyl sulfate
STEMI = ST-segment elevation
myocardial infarction
TILRR = toll-like and
interleukin-1 receptor regulatorProteoglycans and glycosylated proteins act as
co-receptors in a number of regulatory systems.
Recruited to the receptor complex, they control
receptor function, ligand binding, and extracellular
interactions associated with aberrant signal activation
and disease (6–8). The IL-1 receptor type I (IL-1RI),
and its ligand, the cytokine IL-1, are potent activators
of nuclear factor-kappa B (NF-kB) and intrinsically
linked with acute and chronic inﬂammation (9). Dys-
regulation of NF-kB and IL-1-induced gene activity
underlie development and progression of conditions
such as atherosclerosis (10,11). Our earlier studies
identiﬁed Toll-like and IL-1 receptor regulator (TILRR)
(FREM1 isoform 2) (12), a cell surface proteoglycan, as
an IL-1RI co-receptor (13,14). We have demonstrated
that TILRR association with IL-1RI causes enhanced
expression of IL-1RI and increased recruitment of the
MyD88 adapter to the Toll/interleukin-1 receptor
homology domain of IL-1RI (13). Further, we have
shown that the resulting increase in signal ampliﬁca-
tion at the level of the receptor complex directs TILRR
control of aberrant activation of NF-kB and inﬂam-
matory genes.
The present study investigates the role of TILRR in
host defense and disease and demonstrates that
TILRR is highly expressed in areas of vascularinﬂammation and lung ﬁbrosis. Character-
ization of the inﬂammatory phenotype of our
TILRR knockout (KO) mouse shows that
changes in IL-1 receptor levels, signal trans-
duction, and inﬂammatory gene activity,
caused by genetic deletion, are consistent
with molecular mechanisms of TILRR func-
tion identiﬁed in our published in vitro
studies (13,14). Using well-established
models of vascular disease we demonstrate
that TILRR KO and antibody blocking lead to
reductions in monocyte activation, inﬂam-
matory gene activity, and disease progres-
sion, without causing development of
vulnerable plaques. Taken together our re-
sults suggest that TILRR is a central regulator
of inﬂammatory responses related to development of
vascular disease, and that it may constitute a highly
speciﬁc therapeutic target.
METHODS
MOUSE STRAINS. TILRR – / – mice . Mice were derived
by the Center for Mouse Genome Modiﬁcation (Uni-
versity of Connecticut, Farmington, Connecticut).
The mouse TILRR transcript is encoded within a
genomic region spanning across exons 24 to 36 of the
Frem1 gene, and the amino terminus of the TILRR
protein from aa1-17 is encoded in the intron preced-
ing exon 24 of Frem1. To create a null allele for
TILRR, LoxP sites were inserted ﬂanking exons 24
and 25 (Supplemental Figure 1). The targeting vector
was prepared by recombineering according to Lee
et al. (15). Brieﬂy, we ﬁrst retrieved approximately
12.8 kb of Frem1 genomic sequence spanning 4 kb
upstream of exon 24 to 3 kb downstream of exon
26 from the BAC, RP23-365E9, into PL253 containing
the herpes simplex virus thymidine kinase negative
TABLE 1 TILRR KO Genotyping Primers
Primer Name Primer 50 – 30
Lox gt forward CTG GGT GGC ATC TAG TAT TC
Lox gt reverse CCC GAG ATT GCA GAG ATT CT
Frt gt forward GAC GTC TGG AGA ACA CAA CA
Frt gt reverse GAG TTC CTC TTT AGC TCT GC
KO ¼ knockout; TILRR ¼ Toll-like and interleukin-1 receptor regulator.
TABLE 2 Primer Combinations Used to Produce Expected Band
Sizes for TILRR KO Genotyping
Primer Combination Type Expected Band Sizes
Lox forward and reverse WT 233 bps
Lox forward and reverse Floxed 325 bps
Frt forward and reverse WT 25 bps
Frt forward and reverse Floxed 223 bps
Lox forward and Frt reverse WT No product
Lox forward and Frt reverse KO 273 bps
Lox forward, Frt forward, Frt reverse WT 125 bps
Lox forward, Frt forward, Frt reverse KO 273 bps
bps ¼ base pairs; WT ¼ wild-type; other abbreviations as in Table 1.
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ted the 50 LoxP site approximately 800 bp upstream
of exon 24 followed by insertion of Frt-PGKneo-Frt-
LoxP approximately 100 bp 30 downstream of exon
25. The ﬁnal vector contains 50 and 30 arms of 3 and 4
kb, respectively. The vector was linearized by diges-
tion using NotI (restriction endonuclease, which
recognizes the sequence 5’ GC/GGCCGC 3’) and puri-
ﬁed, and subsequently electroporated into mouse
embryonic stem cells derived from F1 (129Sv/C57BL/
6J) blastocyst. Electroporated cells were cultured in
the presence of G418 and gancyclovir (Life Technol-
ogies, Paisley, United Kingdom) 48 h post-
electroporation. Drug-resistant colonies were picked
and screened by long-range polymerase chain reac-
tion (PCR) using primers corresponding to sequences
outside the arms and speciﬁc to the 50 and 30 LoxP
sites to identify targeted embryonic stem clones.
These targeted embryonic stem clones were
expanded and analyzed by long-range PCR for
conﬁrmation before using them for embryonic stem
cell-morula aggregations (KSOM embryo culture me-
dium, overnight, 37C) and development of blasto-
cysts for generation of chimeric animals.
Chimeric animals were bred with ROSA26-Flpe
mice (Jax #003946, Jackson Laboratory, Bar
Harbor, Maine) to remove the PGKneo cassette to
generate the conditional knock-in mice, or Hprt-Cre
mice (Jax #004302) to generate the global KO mice.
C57BL/6J wild-type littermates were used as control
mice.
Low-density lipoprotein receptor–/–/TILRR–/– double KO
mouse. Double knockout mice (TILRR–/–/LDLRR–/–)
were bred using LDLR–/–(Jax 002207) and a conven-
tional cross breeding strategy. Observed genotype
ratios did not differ from those expected.
Apolipoprotein E (ApoE)–deﬁcient (ApoE–/–) mice
(Jax #2052) were obtained from the Jackson
Laboratory.
PCR genotyp ing . Ear clippings were lysed in 50-ml
alkaline lysis reagent (95C, 2 h) before addition of
neutralization reagent (50 ml), and 1 ml used for each
PCR reaction. Each reaction used 12.5 ml BioMixRed
(2, Bioline), 0.6 ml of each primer (10 mM), and 1 ml
of DNA in a total volume of 25 ml (Tables 1 to 4).
Cycling conditions for TILRR KO reaction included
an initial denaturation step (94C, 3 min), followed
by 33 cycles of denaturation (94C, 30 s), annealing
(55C, 30 s) and extension (72C, 15 s) with a ﬁnal
single extension step (72C, 5 min). Cycling condi-
tions for LDLR KO reaction were modiﬁed to
include 40 cycles with an annealing temperature of
65C.IN VIVO DISEASE MODELS. Inﬂammatory responses .
To assess the impact of TILRR KO on inﬂammatory re-
sponses, lipopolysaccharide (LPS) (10 mg/kg) (Enzo Life
Sciences, Exeter, United Kingdom) was injected into the
peritoneum of TILRR–/– mice and control littermates to
induce an acute inﬂammatory response and vehicle,
phosphate-buffered saline (PBS), injections were used as
control. Mice were sacriﬁced at 3 h post-injection and
tissuesprepared and inﬂammatory responses determined
using in vivo models for atherosclerosis and ﬁbrosis, as
described subsequently.
Response to in jury . This was assessed using carotid
ligation, as previously (17). The right carotid artery of
wild-type and TILRR KO mice was exposed and
permanently ligated with a 6-0 suture just below
the bifurcation. The contralateral artery received a
sham ligation. Arteries were harvested from ani-
mals after 28 days following perfusion ﬁxation.
Arteries were embedded in parafﬁn wax, sectioned
and stained for morphometric analysis and
immunohistochemistry.
Atherosclerotic development. LDLR–/–, LDLR–/–/TILRR–/–,
and ApoE–/– mice were kept on a high-fat diet (18% lard
fat, 1% cholesterol, and 0.5% sodium cholate) (Purina
Mills, St. Louis, Missouri) for 12 weeks, from 8weeks of
age, and were housed with a 12-h light–dark cycle at
22C.
To assess the impact of TILRR antibody blocking on
development of atherosclerosis, ApoE–/– mice were
TABLE 3 LDLR KO Genotyping Primers
Primer Name Primer 50 – 30
LDLR Common CCA TAT GCA TCC CCA GTC TT
LDLR WT GCG ATG GAT ACA CTC ACT GC
LDLR KO AAT CCA TCT TGT TCA ATG GCC GAT C
KO ¼ knockout; LDLR ¼ low-density lipoprotein receptor; WT ¼ wild-type.
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immunoglobulin (IgG) (control mice), or with an
antipeptide antibody targeting the TILRR functional
site, described subsequently (intravenous 2/week,
130 mg/kg) (custom made, Eurogentec Ltd., South-
ampton, United Kingdom). Antibody injections were
started at 8 weeks of age and continued throughout
the 12-week experiment. Antibody concentration was
determined based on initial pilot experiments.
Atherosclerosis extent and composition was
determined as described previously and outlined
subsequently (18).
Lung ﬁbros is . ApoE–/– mice were kept on a high-fat
diet and injected with anti-TILRR antibody, or with
PBS or nonspeciﬁc IgG (control mice), as described
previously. Lung tissue was prepared, stained, and
analyzed as outlined subsequently.
Mice were sacriﬁced by exsanguination under
pentobarbital anesthesia. All experiments were per-
formed in accordance with UK Home Ofﬁce legislation
under the 1986 Animals (Scientiﬁc Procedures)
Act, and covered by licenses PPL 70/7992 and PPL
30/3531.
PEPTIDE ANTIBODY DEVELOPMENT. Earlier studies
using alanine-scanning mutagenesis of conserved
residues within the TILRR core protein identiﬁed
a functional site, which caused a 60% reduction in
inﬂammatory responses without affecting IL-1-
induced antiapoptotic signals (13,14). A peptide
(FDSTDLSQRKLRTRG) containing the functional site
at residue D448 was used to develop a blocking
peptide antibody (anti-rabbit, custom, Eurogentec).
The antibody was tested in in vitro assays toTABLE 4 Primer Combinations Used to Produce Expected Band
Sizes for LDLR KO Genotyping
Primer Combination Type Expected Band Size
LDLR Common and LDLR WT WT 167 bps
LDLR Common and LDLR KO KO 350 bps
To analyze TILRR/low-density lipoprotein receptor (LDLR) double KO mice,
genotyping for LDLR and for TILRR were run in parallel. Expected band and sizes
for TILRR/LDLR double KO mice were 273 bps using TILRR primers and 350 bps
using LDLR primers.
Abbreviations as in Tables 1 and 2.determine effects on IL-1-induced activation of NF-kB
regulated inﬂammatory responses and antiapoptotic
signals (Supplemental Figure 2). Cultures were
pre-incubated with the peptide antibody (0, 10, 100,
200 ng/ml) for 2 h before stimulation with IL-1
(109 M, 6 h), and effects on inﬂammatory responses
analyzed by reporter assay using IL-8 as readout, and
antiapoptotic signals determined by monitoring acti-
vation of caspase-3 and -7. Control cultures were
incubated with a nonspeciﬁc IgG.
TISSUE AND SAMPLE PREPARATION. Prote in , DNA,
and RNA extract ion from spleen t i ssue . Spleen
tissue taken from TILRR–/– and wild-type, LPS-injec-
ted mice were ﬂash frozen with liquid nitrogen and
pulverized using pestle and mortar. The disrupted
tissue was lysed in Buffer RLT (AllPrep Kit, Qiagen,
Manchester, United Kingdom) containing 1% b-mer-
captoethanol and homogenized by passing through a
25-gauge needle 10 times. Samples were then pro-
cessed using the AllPrep Kit according to the manu-
facturer’s instructions. Proteins were dissolved in 5%
(w/v) sodium dodecyl sulfate (SDS) containing 1
protease inhibitor cocktail (Roche Diagnostics,
Burgess Hill, United Kingdom) by manual mixing and
heating to 37C. Total protein was quantiﬁed by
bicinchoninic acid assay (Pierce Chemical, Dallas,
Texas). Total DNA and RNA was determined using the
NanoDrop 1000 machine (Thermo Fisher Scientiﬁc,
Loughborough, United Kingdom).
Isolation of bone marrow cells. Femurs of TILRR–/– and
wild-type mice were dissected and adherent tissue
removed. Bones were then washed in 70% ethanol
solution and Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal calf serum and 1% penicillin
streptomycin (Thermo Fisher Scientiﬁc). The epiph-
ysis was removed and the bone ﬂushed with a 21- or
26-gauge hypodermic needle and syringe ﬁlled with
Dulbecco’s modiﬁed Eagle’s medium to extrude the
bone marrow into a Petri dish. The bone marrow was
homogenized by gentle pipetting and the cells coun-
ted using a hemocytometer. Cells were centrifuged
(750 to 1,000 g, 5 min) and resuspended in bone
marrow–derived macrophages differentiation me-
dium (10% fetal calf serum, 20 ng/ml M-CSF) for 7
days. Cells were seeded at 5  106 in 10 cm dish with
bone marrow–derived macrophages differentiation
medium overnight or frozen in liquid nitrogen.
MORPHOLOGY. T issue preparat ion . Vascular and
lung tissue. After perfusion with ice-cold PBS, the
aortic root, brachiocephalic and carotid arteries, and
lungs were ﬁxed in 10% buffered formalin (5 h, 4C),
embedded in parafﬁn, and 5-mm sections mounted
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GmbH, Braunschweig, Germany).
Histo logy . Serial sections of the aortic root and the
brachiocephalic artery, 90 mm apart, were dewaxed in
xylene and rehydrated in a graded series of ethanol
(100%, 90%, 70%, 50%), washed in water and stained
with Alcian blue and elastic van Gieson as described
(19). Brieﬂy, sections were dewaxed in xylene and
rehydrated through graded alcohols and oxidated
using potassium permanganate (0.25%, 30 min),
bleached in oxalic acid (1%) and nuclei counter-
stained with Carazzi’s hematoxylin (2 min), followed
by rinses in acid alcohol (1% hydrochloric acid, 70%
ethanol, 5 min). Following staining with Alcian blue
(1%) in aqueous acetic acid (3%, pH 2.5, 5 min) sec-
tions were washed in water and ethanol (95%),
stained with Miller’s elastin (30 min), rinsed in
ethanol (95%) and distilled water, and incubated with
Curtis’s modiﬁed van Gieson stain (6 min). Sections
stained with Trichrome were incubated in Bouin’s
solution (10 min, 58C) and Weigert’s iron hematox-
ylin solution (5 min), washed (30 s), stained with
Trichrome solution (15 min) (Sigma-Aldrich, St. Louis,
Missouri), and placed in acetic acid (10 s, 0.5%). For
hematoxylin and eosin staining, dewaxed sections
were immersed in hematoxylin (4 min) and rinsed in
tap water, immersed in eosin (1 to 2 min), and
mounted using ProLong Gold Antifade (Life
Technologies).
For collagen staining slides were incubated with
picrosirius red (0.1%, 1 h) (Sigma-Aldrich) or Martius
scarlet blue as described (20) and levels of plaque
collagen expressed as a percentage of the total
surface area. Brieﬂy, sections were dewaxed and
rehydrated in xylene and graded alcohols and stained
with 1% (w/v) Celestine blue (5 min) and counter-
stained with Harris’s hematoxylin (5 min). After
rinsing in tap water and acid alcohol, sections were
rinsed in hot tap water and ethanol (95%), and
stained with 0.5% (w/v) Martius yellow and 2% (w/v)
phosphotungstic acid in 90% (v/v) ethanol (2 min),
and immersed in ponceau de xylidine solution (1%
[w/v] ponceau de xylene/2% [v/v] glacial acetic acid,
10 min). The stain was differentiated using phos-
photungstic acid (1%, 5 min) and sections stained
with methyl blue (5% [w/v] methyl blue in 10% [v/v]
glacial acetic acid, 10 min), washed in acetic acid
(1%, 10 min), and rehydrated through graded series of
alcohols and xylene (2) and mounted using DPX (VWR
International, Lutterworth, United Kingdom).
En face staining of the whole aorta was carried out
as described (21). In brief, the aortas were perfused
with PBS and 10% (v/v) formalin, dissected, ﬁxed in
10% (v/v) formalin, and stored in PBS (overnight,4C). The aorta was opened longitudinally and
stained with Oil Red O stain (Sigma Aldrich), rinsed in
isopropanol (60% [v/v]), stained with 0.3% (w/v) Oil
Red O stain (Sigma-Aldrich) in PBS (30 min), de-
stained in isopropanol (60% [v/v] 20 min) and
washed in distilled water, and images of the exposed
luminal portion of the aorta taken using light
microscopy.
IMMUNOHISTOCHEMISTRY. Sections of vascular
samples were prepared as previously (22). Brieﬂy,
formalin-ﬁxed, parafﬁn-embedded samples were
deparafﬁnized and rehydrated through decreasing
concentrations of ethanol. Sections were treated with
hydrogen peroxidase (3% in PBS) and sodium citrate
solution (10 mM, pH 6.0, Alfa Aesar, Ward Hill,
Massachusetts) (20 min, 95C) to block endogenous
peroxide and induce antigen retrieval, washed in PBS,
and blocked with 10% goat serum or 1% (w/v) nonfat
milk in PBS (30 min). Sections were incubated with
primary antibodies (PBS, 1% bovine serum albumin,
4C, overnight); afﬁnity puriﬁed nonblocking rabbit
peptide polyclonal anti-TILRR (1:50, peptide GNER-
YFWIGL, custom made, Eurogentec), mouse mono-
clonal smooth muscle cell anti-a-actin (1:100, Dako,
Glostrup, Denmark), or rat monoclonal anti-Mac-3
(anti-mouse CD107b; 1:100 or 1/150, Pharmingen,
San Diego, California), followed by incubation with
appropriate secondary antibody, as required: goat
anti-rabbit DyLight 550- or 633-conjugated antibody,
goat anti-mouse DyLight 488–conjugated antibody,
or goat anti-rat DyLight 488–conjugated antibody (all
at 1:200, ImmunoReagents, Raleigh, North Carolina),
or with biotinylated antibodies, followed by a 30-min
incubation with an avidin-biotin complex (Vectasta-
tin Elite ABC kit, Vector Laboratories, Peterborough,
United Kingdom) and 3,3’-diaminobenzidine (DAB),
using well established procedures. Nuclei were
counterstained with Carazzi’s hematoxylin or 4’,6-
diamidino-2-phenylindole (DAPI).
MORPHOMETRY. Images of sections stained for
collagen, vascular smooth muscle cell a-actin and
Mac-3 were analyzed with NIS-Elements software
(Nikon UK Limited, Kingston Upon Thames, United
Kingdom). The size of the plaque area was expressed
as micrometers squared. The amount of collagen,
vascular smooth muscle cells and macrophages in
plaques, and vascular smooth muscle cells in the
medial area were quantiﬁed using a color threshold.
For quantiﬁcation of pulmonary ﬁbrosis, the number
of granulomas and inducible bronchus-associated
lymphoid tissue (iBALT), and the level of pulmonary
vascular remodeling, 3 Trichrome-stained sections
200 mm apart were analyzed for each lung.
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viously, using 10 images per lung section, excluding
areas with tracheal or bronchial tissue, and ﬁelds
graded using the Ralf-Harto Hübner scale (23,24).
Pulmonary muscularization was assessed by
measuring the medial area of vessels with a diameter
above 100 mm.
MICROSCOPY. Microscopy was carried out using a
Nikon E600 microscope (Nikon UK Limited) and
quantitation made using NIS-Elements software.
FLOW CYTOMETRY. Blood (100 ml) from wild-type
and TILRR KO mice was collected 3 h after injection
with LPS (10 mg/kg) or PBS (control) into 1 ml of PBS
containing 5 mM ethylenediaminetetraacetic acid
(EDTA) and erythrocytes were lysed using red blood
cell lysis buffer. Fc receptors were blocked by pre-
incubating with 0.5 to 1 mg of puriﬁed anti-mouse
CD16/CD32 antibodies (eBioscience, San Diego, Cali-
fornia) for 10 min at 4C before staining. Cells were
stained (30 min, 4C) with a combination of
ﬂuorochrome-conjugated antibodies: Paciﬁc Blue
anti-mouse CD11b, PE/Cy7 anti-mouse Ly-6G/Ly-6C,
and PE anti-mouse F4/80 (1 mg/100,000 cells) (Bio-
legend, San Diego, California). For live/dead
discrimination LIVE/DEAD Fixable Blue Dead cell
stain kit, for ultraviolet excitation (Life Technologies)
was used. After ﬁxation O/N in paraformaldehyde
(1%, 4C) cells were analyzed on BD LSRII Flow Cy-
tometer. For color compensation AcCTM anti-rat/
hamster bead kit or AcCTM anti-mouse bead kit in
combination with corresponding antibodies and ArC
Amine Reactive Compensation Bead kit with LIVE/
DEAD Fixable Blue Dead cell stain kit were used.
CELL CULTURE. Mouse ce l l l ines . RAW 264.7 cells
(murine monocyte/macrophage cell line, ATCC) were
propagated in Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal calf serum, and were used in
initial functional in vitro assays.
Mouse pr imary ce l ls . Bone marrow cells from
TILRR–/– and wild-type mice were cultured using
standard conditions of 5% CO2 at 37C in 10% fetal calf
serum Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 20 ng/ml macrophage colony-stimu-
lating factor for 7 days to stimulate differentiation
into bone marrow–derived macrophages. A total of
2  105 cells were seeded in 6-well plates and stimu-
lated the following day with 1 nM recombinant IL-1b
(R&D systems, Abingdon, United Kingdom) for
required time. Cells were lysed in SDS lysis buffer (1%
v/v Triton X, 0.5% [w/v] SDS and 0.1% dimethoxy-4-
chloroamphetamine [w/v]). Lysates were vortexed
and incubated on ice for 20 min, followed by 20 min
centrifugation at 13,000 rpm (4C).MACROPHAGE DIFFERENTIATION. RAW 264.7 cells
were differentiated to M1 or M2 macrophage
subpopulations using conventional procedures by
incubating with LPS (100 ng/ml) and interferon-
gamma (50 ng/ml, R&D systems) or with IL-4 (10 ng/ml),
respectively, for 24 h. Total RNA was isolated using the
RNeasy extraction kit (Qiagen) and complementary
DNA generated by reverse-transcription PCR using a
High Capacity RNA-to-cDNA Kit (Applied Biosystems,
Warrington, United Kingdom) and analyzed by quantita-
tive PCR (qPCR).
WESTERN BLOTTING. Extracted samples were sepa-
rated by SDS–polyacrylamide gel electrophoresis
(4% to 12%) and transferred to nitrocellulose mem-
branes (GE Healthcare, Cardiff, United Kingdom). For
analysis of signaling intermediates, membranes were
blocked using Odyssey blocking buffer (30% in PBS, Li-
Cor, Cambridge,UnitedKingdom) ormilkTris-buffered
saline (5% milk, Tris-buffered saline, 0.1% Tween).
TILRR was detected by an afﬁnity-puriﬁed speciﬁc
nonblocking rabbit peptide anti-TILRR antibody, as
previously (1:1,000, custommade, Eurogentec) (13,14).
Incubation with antibodies against IL-1RI (1:500,
Abcam, Cambridge, United Kingdom), tumor necrosis
factor receptor 1 (TNFRI) (1:250, Abcam), TLR2 (1:1,000,
Novus Biologicals, Abingdon, United Kingdom), TLR4
(1:1,000, Novus Biologicals), inhibitor kappa B alpha
(IkBa) (1:1,000, Santa Cruz Biotechnology, Heidelberg,
Germany), phospho-IkBa (1:1,000, Cell Signaling
Technology, Leiden, the Netherlands), and b-actin
(1:1,000, Santa Cruz) was followed by probing with a
relevant secondary antibody and developed using
LI-COR Odyssey (Li-COR, Biosciences, Lincoln,
Nebraska) and quantitation using ImageJ (64-bit Java)
(National Institutes of Health, Bethesda, Maryland).
LUCIFERASE ASSAY. Cells were seeded in 96-well
plates (Nunc), and transfected with herpes
simplex virus thymidine kinase promoter with
Renilla luciferase expression plasmid (75 ng TKRL)
and IL-8-luciferase (100 ng) using Polyfect (Qiagen)
according to the manufacturer’s instructions. Twenty-
four hours post-transfection, cells were pre-incubated
the anti-TILRR peptide antibody, as described previ-
ously, and stimulated with IL-1b (1010 M or 109 M,
6 h). Luciferase assay was carried out using the
Dual-Luciferase Reporter Assay System (Promega,
Southampton, United Kingdom), according to the
manufacturer’s instructions. Brieﬂy, cells were lysed
in 50 ml passive lysis buffer during shaking (15 min).
Lysate (15 ml) and ﬁreﬂy luciferase (25 ml) were added
to each well and luminescence measured using a
Varioskan plate reader (Thermo Scientiﬁc), and levels
of the TK-RL control plasmid determined after
addition of Stop & Glo (25 ml).
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404CASPASE ASSAY. Caspase activity was determined
using the caspase-3 and -7 Glo Luminometric Assay
(Promega) according to the manufacturer’s protocol.
Seventy-two hours after seeding, cells were washed
with PBS and treated with tumor necrosis factor alpha
(10 ng/ml) plus cycloheximide (10 mg/ml) for 3 h to
induce apoptosis  prior IL-1 (1 nM, 3 h) stimulation.
Cultures were incubated in the presence of caspase-3
and -7 Glo reagent (50 ml/well, 2 h), reactions trans-
ferred to a white walled plate and the luminescence
measured on a Varioskan plate reader.
ENZYME-LINKED IMMUNOSORBENT ASSAY. Cells
were incubated with the TILRR peptide antibody or
with an IgG control, and stimulated with IL-1, as
previous. IL-6 protein levels were measured using a
human IL-6 DuoSet enzyme-linked immunosorbent
assay, according to the manufacturer’s instructions.
TILRR SMALL INTEREFERING RNA. Twenty-four
hours after plating, HeLa cells were transfected with
either ON-TARGETplus Nontargeting small inter-
fering RNA (50 nM, Fisher) or custom TILRR small
interfering RNA (50 nM, Eurogentec), using Dharma-
fect1 (24 ml, Dharmacon, Lafayette, Colorado),
demonstrated to reduce TILRR expression by on
average 70% (13).
MICROARRAY ANALYSIS. Total RNA was harvested
from spleen and blood monocytes of TILRR–/– and
wild-type C57BL/6J mice using the RNeasy kit (Qia-
gen) and RNA quality and concentration determined
using the 2100 Bioanalyzer (Agilent Technologies,
Cheadle, United Kingdom). Samples were labeled
and hybridized using the Affymetrix Gene Chip
Hybridization platform (Affymetrix, High Wycombe,
United Kingdom) and scanned using the Illumina
HiScan SQ in the Shefﬁeld Microarray/Genomics Core
Facility. Gene expression proﬁles were analyzed
using R Bioconductor 2.14 (Bioconductor) and DAVID
6.7 (National Institute of Allergy and Infectious
Diseases [NIAID], NIH) (25,26), and data expressed as
log2-fold change of activity in TILRR–/– relative to
wild-type.
qPCR ANALYSIS. RNA was prepared from extracted
spleen tissue from TILRR–/– and wild-type mice,
injected with LPS (10 mg/kg, Enzo Life Sciences), as
described previously. Extracted and cultured bone
marrow–derived macrophages were lysed using Buffer
RLT and total RNA isolated using RNeasy kit (Qiagen).
One microgram of total RNA was reverse transcribed
to complementary DNA (cDNA) (Applied Biosystems)
and 1 ml was added to standard Taqman qPCR reaction
(Applied Biosystems) containing relevant TaqMan
MGB probes (murine probes): glyceraldehyde
3-phosphate dehydrogenase (GAPDH), chemokineligand 2 (CCL2), C-X3-C motif chemokine ligand 1
(CX3CL1), tumor necrosis factor alpha (TNFa), and
interleukin (IL)-6 (Thermo Fisher Scientiﬁc).
Venous blood samples taken sequentially from
patients on the day of presentation (day 1) and days
7 and 90 following ST-segment elevation myocardial
infarction (STEMI) or non–ST-segment elevation
myocardial infarction (NSTEMI), and venous blood
samples from healthy volunteers were screened for
TILRR expression, using an N-terminal probe
(Thermo Fisher Scientiﬁc). RNA was puriﬁed from
human blood stored in Tempus tubes using Maxwell
16 miRNA Blood Kit (Promega) and the Maxwell 16
Instrument (Promega) as per manufacturer’s in-
structions. Results were analyzed by RQ Manager
analysis software (Thermo Fisher Scientiﬁc). Critical
threshold values were normalized to endogenous
GAPDH control. Readings using a C-terminal probe for
FREM1 (Thermo Fisher Scientiﬁc) were subtracted
from the data.
AGENT-BASED MODELING. Simulations comparing
activation in the presence and absence of TILRR
ampliﬁcation were carried out using the agent-based
modeling representing activation of the NF-kB
network, as described (27-32).
PROTEIN STRUCTURE MODELING AND DOCKING.
The tertiary structure model of TILRR
(NP_001171175.1) was built using multiple-threading
alignments and iterative fragment assembly in the
de novo I-Tasser Zhang Server (33). The extracellular
domain of IL-1RI was generated in Swiss-Model (34),
using IL-1RI from the resolved crystal structure
complex (PDB:4DEP) (35). The protein-docking
model was predicted using generated PDB ﬁles
in Gramm-X (36). Protein tertiary structure models
were viewed and modiﬁed in MolSoft ICM
Browser and protein structure template quality
scored (37,38).
STATISTICAL ANALYSIS. Data showing normal dis-
tribution were analyzed by Student’s t test or 1-way
analysis of variance (Prism 6, GraphPad Software,
San Diego, California), and using Dunnett’s test or
Tukey’s post hoc test for multiple comparisons, and
are presented as mean  SEM.
All in vitro and ex vivo experiments included
triplicate samples and statistical analysis was based
on 3 to 5 independent experiments. Morphological
data were obtained from 5 to 12 control animals and
5 to 15 experimental animals. Statistical analysis
was based on average readings for each animal,
which were calculated based on 3 to 7 independent
measurements from serial sections, 90 or 200 mm
apart.
FIGURE 1 TILRR Controls IL-1RI Levels, Signal Ampliﬁcation, and Gene Activity
(A) Quantitative polymerase chain reaction (qPCR) of TILRR expression in raw cells, stimulated with lipopolysaccharide (LPS) (6 h) over a range of concentrations, as
indicated. Data are expressed relative to levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and show mean  SEM. n ¼ 3.0 mg/ml LPS versus 0.1mg/ml
LPS; 0 mg/ml LPS versus 1 mg/ml LPS, **p < 0.01. (B) qPCR of Toll-like and interleukin-1 receptor regulator (TILRR) expression in M1- and M2-like macrophages and
undifferentiated cultures (control). Data are expressed relative to levels of GAPDH and show mean  SEM. n ¼ 3, **p < 0.01,***p < 0.001. (C) Fluorescence-activated
cell sorting analysis of inﬂammatory monocytes from wild-type (WT) and TILRR knockout (KO) mice injected with LPS (10 mg/kg). Data are expressed as percent of
total monocyte levels and show mean  SEM. n ¼ 6 WT, n ¼ 9 TILRR KO. Levels in TILRR KO mice versus levels in WT mice, **p < 0.0088. (D) Western blots of
interleukin-1 receptor type I (IL-1RI), tumor necrosis factor receptor (TNFR), Toll-like receptor 4 (TLR4), and Toll-like receptor 2 (TLR2) expressions in spleen from WT
and TILRR KO mice. (E) Quantitation of Western blots as in D showing receptor levels in TILRR KO cells relative to levels in WT cells, using to b-actin as loading control.
The graph shows mean  SEM, n ¼ cells from 4 to 6 WT mice and 4 to 6 TILRR KO mice for each receptor. Levels of IL-1RI, TNFR, TLR4, and TLR2 in TILRR KO mice
are expressed as percent of levels of the respective receptor in WT mice, IL-1RI expression in TILRR KO mice versus IL-1RI expression in WT mice. ****p < 0.0001. (F)
Western blot analysis of interleukin (IL)-1–induced (109 M) inhibitor kappa B alpha (IkBa) degradation in bone marrow–derived macrophages from WT and TILRR KO
mice. (G) Quantitation of Western blots as in F showing IL-1–induced IkBa degradation in WT (circles) and TILRR KO (squares) cells. Data are expressed as percent of
IkBa levels in unstimulated WT and TILRR knockout cells, respectively (time 0) and show mean  SEM. n ¼ peripheral blood mononuclear cells from 4 WT mice and 4
TILRR KO mice. Levels in TILRR KO cells versus levels in WT cells at 30 min. *p ¼ 0.0124. (H) qPCR of bone marrow–derived macrophages from TILRR KO mice shows
reductions in chemokine ligand 2 (CCL2) and C-X3-C motif chemokine ligand 1 (CX3CL1). Data are expressed as percent activation of the respective gene in cells from WT
mice and show mean  SEM. n ¼ cells from 4 TILRR KO mice and 4 WT mice. CCL2 expression in TILRR KO cells versus expression in WT cells, **p ¼ 0.0022; CX3CL1
expression in TILRR KO cells versus expression in WT cells, *p ¼ 0.0482. (I) qPCR of spleen samples from TILRR KO mice shows reductions in proinﬂammatory
cytokines tumor necrosis factor (TNF)-a and IL-6. Data are expressed as percent activation of the respective gene in spleen samples from WT mice, and show mean 
SEM. n ¼ 5 WT and 5 TILRR KO mice. TNF-a expression in TILRR KO cells versus expression in WT cells, ***p ¼ 0.0009. IL-6 expression in TILRR KO cells versus
expression in WT cells, *p ¼ 0.0236.
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p values are included in the respective legends.
RESULTS
THE TILRR KO MOUSE EXHIBITS IMPAIRED CONTROL OF
NF-kB AND REDUCED GENE ACTIVITY. Initial in vitroexperiments using qPCR demonstrated that LPS stim-
ulation induced a concentration-dependent increase
in TILRR expression in mouse macrophages, and
showed that expression levels in M1 macrophages
were increased by about 3-fold, from 1.50  0.63 rela-
tive to GAPDH in control cells to 4.55  0.82, whereas
levels in the M2 phenotype were similar to levels in
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406undifferentiated cultures (1.57  0.44) (Figures 1A
and 1B). The relevance of TILRR expression in mono-
cyte activation was supported by subsequent in vivo
experiments using a TILRR KO mouse (Supplemental
Figure 1), which demonstrated that TILRR deletion
caused a reduction in activated blood monocytes from
28.13  5.04% to 11.34  1.81% (Figure 1C).
Characterization of the inﬂammatory phenotype
of the TILRR KO mouse demonstrated effects on
IL-1 receptor levels, signal transduction, and gene
regulation. Western blot analysis of spleen samples
showed that IL-1RI expression in TILRR KO mice was
signiﬁcantly reduced, with levels corresponding to
55  7% of expression wild-type mice, whereas levels
of tumor necrosis factor receptor (85  17%), Toll-like
receptor 4 (124  23%), and Toll-like receptor 2
(104  14%) were not signiﬁcantly different from
control mice (Figures 1D and 1E). Subsequent
experiments assessed effects of genetic deletion of
TILRR on IL-1–induced activation of NF-kB, using
degradation of the inhibitor IkBa as readout. Thirty
minutes of IL-1 stimulation of peripheral blood
mononuclear cells (PBMCs) from wild-type mice
caused, as expected, a successive reduction in IkBa to
levels corresponding to 40  4% of levels present
before activation (Figures 1F and 1G). In comparison,
inhibitor levels in cells from TILRR KOmice, subjected
to the same treatment, were signiﬁcantly higher, cor-
responding to 76  9% of initial levels. The reduction
in inhibitor degradation from 60% in control PBMCs to
24% in the TILRR KO cells is consistent with impaired
induction of NF-kB, and agrees with results from our
earlier in vitro experiments, demonstrating that
inhibiting TILRR function signiﬁcantly reduces IL1-
induced activation of the pathway (13,14,27). In silico
analysis using an agent-based model of NF-kB regu-
lation in TILRR KO cells predicted the observed
changes in receptor levels and signal ampliﬁcation to
have signiﬁcant effects on activation of inﬂammatory
genes (Supplemental Figures 3A and 3B). Microarray
analysis of blood and spleen samples from LPS-
injected TILRR KO mice demonstrated pronounced
reductions in activation of proinﬂammatory regula-
tors compared with levels in wild-type mice
(Supplemental Figure 4). Results were conﬁrmed by
qPCR analysis. Figure 1H shows reduced induction of
chemokine ligand 2 (CCL2) (45.0  2.4%) and C-X3-C
motif chemokine ligand 1 (CX3CL1) (69.55  3.46%)
in bone marrow–derived macrophages from TILRR KO
mice compared with levels measured in wild-type
cells. Similarly, analysis of spleen samples from
TILRR KO mice demonstrated pronounced reductions
in cytokines, including TNFa (55.8  4.5%) and IL-6
(45.8  22.0%) (Figure 1I).Subsequent studies assessed the role of TILRR in
cardiovascular disease and lung ﬁbrosis, and evalu-
ated its potential as a therapeutic target.
RESPONSE TO INJURY IS SIGNIFICANTLY REDUCED
IN THE TILRR KO MOUSE. Initial experiments used an
in vivo carotid ligation model to monitor responses to
tissue injury in the TILRR KO mouse. Immunostain-
ing of arterial cross sections from wild-type mice
demonstrated high levels of TILRR expression at the
ligation site (Figure 2A). A pronounced thickening of
the neointimal layer of the vessel in control animals,
induced in response to ligation, was signiﬁcantly
reduced in TILRR KO mice subjected to the same
treatment (Figures 2B and 2C). Quantitation revealed a
reduction in the average Neointima of about 50%
(from 1,292  211 mm2 to 629  188 mm2) and a decrease
in the maximum thickness of about 60% (from 2,476
 388 mm2 to 971  141 mm2) (Figures 2D and 2E).
Further, the cell density in the adventitia was
signiﬁcantly reduced, from 0.108  0.015 cells/mm2 in
the wild-type mice to 0.04  0.01 cells/mm2 in the
TILRR KO mice (Figure 2F).
TILRR IS HIGHLY EXPRESSED IN PBMCs FROM PATIENTS
DIAGNOSED WITH MYOCARDIAL INFARCTION AND IN
THE ATHEROSCLEROTIC PLAQUE. Peripheral blood
mononuclear cells from patients with STEMI and
NSTEMI types of acute myocardial infarction showed
a progressive increase in TILRR expression. TILRR
messenger RNA levels in control samples, normalized
to the internal control, GAPDH, as described in the
Methods, were on average 1.22  0.18 (Figure 3A).
Levels in samples from patients diagnosed with
STEMI-type acute myocardial infarction were 1.97 
0.41, 3.20  1.00, and 3.27  0.96 on days 1, 7, and 90
after diagnosis, respectively. Corresponding values
for patients with NSTEMI-type myocardial infarction
were 1.98  0.64, 2.59  0.50, and 2.71  0.38.
Immunostaining of the aortic root and the bra-
chiocephalic artery from ApoE–/– and LDLR–/– mice,
fed a high-fat diet, demonstrated high levels of TILRR
expression within vascular lesions (Figure 3B, top
image, blue arrow). In contrast, levels were low or
undetectable in tissue surrounding the plaque and in
unaffected vessels (Figure 3B, white arrows, top and
bottom images).
TILRR KO REDUCES THE SIZE AND CHANGES THE
CHARACTERISTICS OF ATHEROSCLEROTIC LESIONS. A
subsequent set of experiments used LDLR–/–/
TILRR–/– DK mice to evaluate the impact of genetic
deletion of TILRR on development and characteris-
tics of atherosclerosis. Histological analysis revealed
pronounced reductions in plaque development in
the aortic root and the brachiocephalic artery
FIGURE 2 Response to Injury Is Signiﬁcantly Reduced in the TILRR-Knockout Mouse
(A) Immunohistochemistry of a cross-section of a carotid artery in a WT mouse subjected to 4 weeks of ligation. Staining using a nonblocking
anti-TILRR antibody followed by a DyLight Fluor-conjugated secondary antibody shows high levels of TILRR expression (red). Scale
bar ¼ 150 mm. Trichrome staining of cross-sections of carotid arteries after 4 weeks of ligation in (B) a WT mouse and (C) a TILRR KO mouse.
Arrows indicate thickness of the neointima in response to treatment. Scale bar ¼ 150 mm. (D to F) Quantitation of measurements from cross
sections as in B and C shows (D, E) a signiﬁcant reduction in the thickness of the neointima and (F) a decrease in cell number in the
adventitia in TILRR KO mice compared with levels in WT mice. Data are expressed as (D, E) area (mm2) and (F) cell number per mm2 and show
mean  SEM. n ¼ 6 WT mice, 7 TILRR KO mice. TILRR KO mice versus WT mice, (D) *p ¼ 0.038, (E) **p ¼ 0.0045, (F) **p ¼ 0.0014.
Abbreviations as in Figure 1.
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407(Figure 3C). Quantitation showed that plaque levels
in the brachiocephalic artery, which corresponded to
26.29  5.23% of the cross-sectional area of the
vessel in the LDLR–/– mice, used as control mice,
was reduced to 15.92  2.88% in the DK mice
(Figure 3D). Further, plaque levels in the descending
aorta were reduced from 8.3  2.5% to 1.9  0.5% of
the cross-sectional area of the vessel (Figure 3E).
Characterization of the plaques revealed a 35% in-
crease in collagen content in lesions from the DK
mice (32.50  1.29%) compared with control mice
(24.17  1.22%) and a 75% reduction in macrophage
levels from 22.25  2.59% to 6.25  0.84% (Figures
3F and 3G).
BLOCKING TILRR FUNCTION REDUCES PROGRESSION OF
ATHEROSCLEROSIS. A subsequent set of experiments
used the ApoE–/– mouse model to establish theimpact of antibody blocking of TILRR function on
progression of atherosclerosis. These studies used a
blocking peptide antibody, which was developed
to target the TILRR functional site at residue
D448, identiﬁed in our earlier study (13). Three-
dimensional modeling of the receptor complex
predicted the residue to be located in the area of
TILRR–IL-1RI association (Supplemental Figures 2A
and 2B). In vitro studies, carried out to assess the
impact of the peptide antibody on IL-1–induced re-
sponses, demonstrated a concentration-dependent
reduction in activation of inﬂammatory genes
(Supplemental Figure 2C). Levels, expressed relative
to activities in cultures incubated with a nonspeciﬁc
IgG control, were reduced from 1.00  0.07 to
0.74  0.09 at 0.1 mg/ml and to 0.61  0.05 at
0.2 mg/ml. In contrast, parallel experiments showed
FIGURE 3 TILRR KO Signiﬁcantly Reduces Progression of Atherosclerosis in LDLR–/– TILRR–/– (DK) Mice
(A) TILRR expression levels in blood samples from patients with myocardial infarction (ST-segment elevation myocardial infarction [STEMI],
light gray bar; non–ST-segment elevation myocardial infarction [NSTEMI], dark gray bar) at diagnosis, day 1, and at days 7 and 90. Values are
mean  SEM. n ¼ 6 to 11 triplicate samples per group and time point. TILRR expression levels in each group of patient samples are compared
with levels in healthy control samples (black bar). STEMI day 7, *p ¼ 0.0442; day 90, *p ¼ 0.0329. NSTEMI day 7, *p ¼ 0.0445; day 90,
*p ¼ 0.0405. (B) Immunohistochemistry of an atherosclerotic plaque in the brachiocephalic artery, using a nonblocking anti-TILRR anti-
body, followed by a DyLight Fluor-conjugated secondary antibody, shows increased levels of TILRR expression within the lesion (top image,
blue arrow), with low levels in the surrounding area (top image, white arrow) and in a healthy vessel (bottom image, white arrow). TILRR
(red), nuclear stain (4’6,-diamidino-2-phenylindole, blue). Scale bar ¼150 mm. (C) Cross-sections of the aortic root (top) and brachiocephalic
arteries (bottom) of LDLR–/– mice (control, left) and LDLR–/–/TILRR–/– mice (double knockout [DK], right), stained with Alcian blue & van
Gieson. Scale bar ¼ 500 mm (aortic root), 200 mm (brachiocephalic artery). Arrowheads point at plaques in arteries from control mice. (D, E)
Quantitation, using images such as in C, shows levels of atherosclerotic plaques in (D) the brachiocephalic artery and (E) the descending aorta
in DK mice and control mice. Data are expressed as percent of total area and show mean  SEM. (D) n ¼ 12 control mice, 15 DK mice. (E) n ¼
6 control mice, 9 DK mice. Levels in DK mice versus levels in control mice, (D) *p ¼ 0.0396; (E) **p ¼ 0.004. (F) Quantitation of collagen
content following staining of sections using Martius scarlet blue. Data are expressed as percent area stained for collagen in control and DK
mice and show mean  SEM. n ¼ 6 control mice, 6 DK mice. Levels in DK mice versus levels in control mice, ***p ¼ 0.0004. (G) Quantitation
of macrophage levels in plaques from control and DK mice following staining of sections using anti-Mac-3. Data are expressed as percent
stained area and show mean  SEM. n ¼ 5 control, 5 DK mice. Levels in DK mice versus levels in control mice, **p ¼ 0.003. Abbreviations as
in Figure 1.
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FIGURE 4 Administration of a Peptide Antibody Targeting the TILRR Functional Site Reduces Development of Atherosclerosis
(A) Fluorescence-activated cell sorting analysis of GR1þ and GR1– blood monocytes as described in the Methods from apolipoprotein E–
deﬁcient (ApoE–/–) mice on a high-fat diet (control, top) and littermates injected with a blocking anti-TILRR peptide antibody 2 times/week
for 12 weeks (bottom). (B, C) Quantitation of data from experiments such as in A shows (B) high levels of GR1þ monocytes in samples from
control animals (black bar) and reduced levels in TILRR antibody–injected mice (light gray bar) and (C) low levels of unactivated GR1–
monocytes in control mice (black bar) and high levels in samples from TILRR antibody-injected mice (light gray bar), with no change in total
levels. Data show (B) GR1þ and (C) GR1– monocytes expressed as percent of total. Values are mean  SEM. n ¼ 5 control mice (black bar), 5
TILRR antibody–injected mice (light gray bar). Levels in antibody-injected mice versus levels in control mice, (B) **p ¼ 0.0065; (C) **p ¼
0.0064. (D) Collagen-stained sections of aortic root (top) and brachiocephalic artery (bottom) from control ApoE–/– mice (left, arrowhead
shows ﬁbrous cap) or TILRR antibody–injected mice (right). Scale bar ¼200 mm. (E, F)Morphometry of (E) plaque area and (F) and collagen
content in the brachiocephalic artery in control (black bar) and TILRR antibody–injected (light gray bar) mice. Data are expressed as (E)
plaque area  103 and (F) percent area of total, and show mean  SEM. n ¼ 9/6 control mice, 8/6 TILRR antibody–injected mice. Levels in
antibody-injected mice versus levels in control mice, (E) *p ¼ 0.0434; (F) *p ¼ 0.029. (G) Sections of brachiocephalic arteries as in panel D
were stained using an anti–smooth muscle cell (SMC) a-actin antibody (green) and nuclear staining (DAPI, blue). Scale bar ¼ 50 mm. (H, I)
Quantitation of smooth muscle cell content in the (H) media and (I) plaques in sections as in panel (G). Data show stained area expressed as
percent of total and represent mean  SEM. n ¼ 7 control mice (black bar), n ¼ 5 TILRR antibody–injected mice (light gray bar), for each
graph. Levels in antibody-injected mice versus levels in control mice, (H) *p ¼ 0.0414; (I) *p ¼ 0.0459. (J) Sections of brachiocephalic artery
from control (left) and TILRR antibody treated mice (right) stained for Mac3 (macrophage marker, green). Scale bar ¼150 mm. (K)
Quantitation of macrophage content in sections of the brachiocephalic artery as in J. Data show stained area expressed as percent of total
and represent mean  SEM. n ¼ 8 control mice (black bar), 6 TILRR antibody–injected mice (light gray bar). Levels in antibody-injected
mice versus levels in control mice, *p ¼ 0.0214. Gr-1 ¼ Myeloid differentiation antigen of the Ly-6 family, (Ly-6G/Ly-6C; TILRR ¼ Toll-like
and interleukin 1 receptor regulator.
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410that antibody blocking had no impact on IL-1–
induced antiapoptotic signals, which at levels
of 0.90  0.04 and 0.96  0.05 at 0.1 mg/ml and
0.2 mg/ml of TILRR antibody, respectively, were
not statistically different from control cultures
(1.04  0.04) (Supplemental Figure 2D).
Repeated injections of the blocking TILRR anti-
body over 12 weeks had no impact on the level of total
monocytes, but caused signiﬁcant changes in the
proportion of monocyte phenotypes. Activated (Gr1þ)
blood monocytes were reduced from 63.78  3.55% in
control mice to 45.63  2.81% in antibody-injected
mice, whereas the fraction of the unactivated
phenotype (Gr1–) was increased from 35.87  3.39% to
53.55  2.92% (Figures 4A to 4C).
Histological analysis revealed pronounced re-
ductions in plaque development in the aortic root and
the brachiocephalic artery (Figure 4D). Quantitation
showed a decrease in the plaque area from 33.53 
3.97  103 mm2 to 20.67  3.74  103 mm2 in the bra-
chiocephalic artery, corresponding to a reduction
close to 40%, and similar to effects observed in the
DK mice (Figure 4E, see Figures 3C and 3D). Charac-
terization of the lesions demonstrated an increase in
the collagen content from 17.63  4.36% to
36.67  6.30%, and in the number of smooth muscle
cells in the media from 6.7  1.2% to 12.3  2.3% and
in the plaque area from 0.20  0.10% to 0.93  0.36%
(Figures 4F to 4I). In addition, antibody blocking
caused a reduction in macrophage content from
22.0  6.0% to 3.3  1.2% of the total area, in agree-
ment with effects observed in the DK mice, and
consistent with an increase in plaque stability
(Figures 4J and 4K, see Figures 3F and 3G).
INCREASED TILRR EXPRESSION CONTROLS INFLAMMA-
TORY RESPONSES IN THE LUNG. A parallel set of ex-
periments examined the impact of TILRR antibody
blocking on levels of lung granulomas and ﬁbrosis in
ApoE–/– mice (23). Immunohistochemistry of cross
sections of the lung in control mice demonstrated
high levels of TILRR expression correlating with
inﬁltrating macrophages (Figure 5A). Staining was
particularly prominent within iBALT. Macrophage
levels were reduced from 26.67  2.60/0.15 mm2 to
12.71  1.77/0.15 mm2 following antibody adminis-
tration (Figure 5B). In addition, antibody targeting
reduced the level of lung ﬁbrosis observed in control
mice, resulting in a decrease in the ﬁbrotic grade
from 3.23  0.50 to 1.89  0.28 (Figures 5C and 5D).
Quantitation revealed a 50% reduction in the
number of lung granulomas from 0.50  0.10/mm2 to
0.21  0.05/mm2, and a 75% decrease in the level ofiBALT lesions from 3.84  1.05  103/mm2 to 0.92 
0.64  103/mm2 (Figures 5E to 5G). Immunostaining
revealed high levels of TILRR expression in mono-
cytes surrounding muscularized vessels in the lung
(Figure 5H). Blocking TILRR function caused a sig-
niﬁcant reduction in the pronounced vessel thickness
in the medial area, characteristic of the condition,
from 2,510.0  317.0 mm2 to 1,606.0  46.2 mm2
(Figures 5I and 5J).
DISCUSSION
These studies establish a central role for the IL-1RI
co-receptor TILRR in disease. The results are
consistent with our earlier work, which identiﬁed
TILRR as a potent regulator of IL-1-induced inﬂam-
matory responses (13,14,27,39). We use in vitro and
in vivo experiments, which include a recently
derived TILRR KO mouse, together with in silico
modeling to demonstrate effects on IL-1 receptor
function, NF-kB control and gene activity, and to
establish the role of TILRR in response to injury and
vascular disease. We show that TILRR levels are low
in healthy tissue and that expression is markedly
increased both in the atherosclerotic plaque and in
peripheral blood mononuclear cells from patients
with myocardial infarction. The TILRR KO mouse
exhibits reduced IL-1 receptor levels, and impaired
NF-kB signaling and gene activity, but retains partial
IL-1RI function. We demonstrate that genetic dele-
tion of TILRR and antibody targeting of the TILRR
functional site reduce development of atheroscle-
rosis, with lesions exhibiting characteristics of stable
plaques. In addition, our data show that blocking
TILRR function reduces lung ﬁbrosis in a mouse
model.
THE RELEVANCE OF PROTEOGLYCANS IN
SIGNALING RECEPTOR FUNCTION. The potentiating
effect by TILRR on ligand-induced activation of the
IL-1 signaling receptor is analogous to control of TGF-
beta receptor complex by betaglycan (also named,
transforming growth factor-beta receptor III,
TGFBR3) and of the ﬁbroblast growth factor receptor
(FGFR) by Syndecan 4 (6,7). The suggested role of
these highly glycosylated co-receptors in enhancing
the range and sensitivity of signal control is consis-
tent with their expression in amphibians and higher
vertebrates (39).
MECHANISMS UNDERLYING TILRR CONTROL OF
IL-1RI. The marked reduction in activity induced by
antibody blocking of TILRR function is likely a direct
consequence of disruption of the TILRR/IL-1RI
FIGURE 5 TILRR Antibody Administration Reduces Inﬂammatory Responses in the Lung
(A)Macrophages in lung sections from ApoE–/– mice fed a high-fat diet (left, Mac-3 green) and inducible bronchus-associated lymphoid tissue
(iBALT) structures (inset) show high TILRR expression (right, red). Scale bar ¼ 150 mm. (B) Quantitation of macrophages from images as in
A. Data are expressed as number of macrophages per 0.15 mm2 and show mean  SEM. n ¼ 9 control mice (black bar), 7 TILRR antibody–
injected mice (light gray bar). Levels in antibody-injected mice versus levels in control mice, ***p ¼ 0.001. (C) Trichrome staining of lung
sections from ApoE–/– mice from control (left) and mice injected with the anti-TILRR peptide antibody (right). Scale bar¼150 mm. (D) Fibrous
grade, (Ralf-Harto Hübner scale) in control (black bar) and TILRR antibody–injected (light gray bar) mice. Data show mean  SEM, n ¼ 9
control, n¼ 7 TILRR antibody–injectedmice. Levels in antibody-injected mice versus levels in control mice, *p¼0.0472. (E)Granulomas (arrow)
and iBALT (arrowhead) in lung tissue from an ApoE–/– mouse. Scale bar¼150 mm. (F, G) Quantitation of sections as in panel E shows (F) levels
of granulomas and (G) iBALT structures in control mice (black bar) and TILRR antibody–injected mice (light gray bar). Data are expressed as
number of structures per cross-sectional area, as indicated. n 9 control mice, 7 antibody-injected mice. Levels in antibody-injected mice versus
levels in control mice, (F) *p ¼ 0.0263; (G) *p ¼ 0.0452. (H) Lung section from a control animal with muscularized vessels with TILRR
expression in surrounding tissue (top; TILRR, red; SMC a-actin, green; DAPI, blue). Trichrome staining (bottom). Scale bar ¼ 75 mm. (I)
Muscularized vessels in a control (top image) and in a TILRR antibody–treated mouse (bottom image). Scale bar¼ 75 mm. (J)Morphometry of
medial area in vessels from control (black bar) and antibody-injected mice (light gray bar). Values are mean SEM. n ¼ 7 control, n ¼ 7 TILRR
antibody–injected mice. Levels in antibody-injected mice versus levels in control mice, *p ¼ 0.0152. Abbreviations as in Figures 1 and 4.
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411complex following blocking of the 448 residue, which
is located within the predicted region of protein–
protein association (13,14,27). A mechanism involving
alterations in TILRR binding to the receptor complexis consistent with results from our previous studies,
which show that TILRR function is dependent on its
interaction with the signaling receptor (13). It is also in
agreement with effects of inhibiting co-receptor
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412binding in the Toll-like receptor 4 system, and
suggests that changes in receptor confor-
mation contribute to the reduction in signal activation
(40–42). Such alterations are likely to directly impact
MyD88 recruitment during activation, a key step in
TILRR control of inﬂammatory responses (13,14). The
potential signiﬁcance of the 448 site is further
highlighted by its recent identiﬁcation as a single
nucleotide polymorphism by the 1000 Genomes Proj-
ect (International Genome Sample Resource).
CONSEQUENCES FOR TILRR REGULATION OF IL-RI
ON INFLAMMATORY RESPONSES. The changes in
IL-1 receptor function and the decrease in NF-kB
signal activation in the TILRR KO mice, and induced
by antibody blocking, are likely responsible for the
reductions in monocyte inﬁltration and activation in
the vascular lesions and in the lung. Together with
the reduced activity of genes known to be central to
development of atherosclerosis and the ensuing
decrease in IL-1 production, such changes are likely
to have a signiﬁcant impact on inﬂammatory
response levels and progression of the disease
(10,11,43,44).
THE IMPACT OF TILRR AND IL-1RI BLOCKING ON
DEVELOPMENT OF ATHEROSCLEROSIS. The central
role of NF-kB and the IL-1 regulatory system in pro-
gression of atherosclerosis is well documented, and
signiﬁcant efforts are being made to explore ﬁndings
from laboratory research in translational projects
(45,46). This study used well-characterized models
of atherosclerosis and vascular inﬂammation, and
screening of patient samples to demonstrate a cen-
tral role for TILRR in fundamental mechanisms of
inﬂammation in vivo, and in development of
vascular disease. Future studies, assessing the
impact of therapeutic blockade of TILRR on estab-
lished atherosclerosis, and on mechanisms underly-
ing changes in lipid metabolism and plaque rupture,
will include additional in vivo models with charac-
teristics relevant for speciﬁc aspects of disease
development (47).
Our results show that genetic deletion of TILRR
or antibody blocking reduces inﬂammatory re-
sponses and decreases lesion formation during
development of atherosclerosis, and thus broadly
agree with the impact of blocking the signaling IL-1
receptor, IL-1RI (45,48). However, in contrast to the
vulnerable plaques observed following IL-1RI dele-
tion, characterization of lesions following blocking
TILRR function revealed high levels of smooth
muscle cells and collagen, characteristics of the
stable plaque phenotype (48). The difference in theplaque phenotype may reﬂect the less pronounced
effects on IL-1 receptor function resulting from
genetic deletion of TILRR, than reported for IL-1RI
KO mice (49). In addition, it may be a conse-
quence of reductions in proinﬂammatory senescent
smooth muscle cells, in combination with main-
tained antiapoptotic signals (50). The importance of
retaining antiapoptotic signals is consistent with
our data on TILRR antibody blocking, which
showed signiﬁcant reductions in inﬂammatory re-
sponses but had no impact on caspase activity.
Further, it suggests that selective inhibition of in-
ﬂammatory responses, made possible through tar-
geting the TILRR functional site, may reduce the
risk of plaque rupture and related complications
(51,52). In addition, due to its high expression in
inﬂamed areas, blocking TILRR is expected to allow
site-speciﬁc targeting of dysregulated activation in
inﬂamed areas and reduce the impact on overall
tissue function.
CONCLUSIONS
The results are consistent with our earlier work and
show that TILRR controls IL-1-induced activation of
NF-kB and inﬂammatory genes and directs signal
ampliﬁcation during host defense responses and
vascular disease development. Conclusions are sup-
ported by data showing increased TILRR expression
within vascular inﬂammatory lesions, and by the
pronounced reductions in aberrant inﬂammatory
activation and disease progression observed by
genetic deletion of TILRR and by antibody blocking.
Our results highlight the importance of receptor
complex composition in disease development and
suggest that TILRR may provide an easily accessible
therapeutic target for subtle site- and signal-speciﬁc
inhibition of inﬂammatory activation during devel-
opment of vascular disease.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
cytokine IL-1 and its signaling receptor IL-1RI are central
regulators of vascular disease. Genetic deletion of IL-1RI
and antibody blocking of IL-1 responses in animal models
reduce development of atherosclerosis but result in
development of vulnerable plaques, in part through
increased smooth muscle cell apoptosis. Our ﬁndings
demonstrate that using a more moderate approach, tar-
geting the co-receptor TILRR, a cell surface proteoglycan
that associates with the signaling receptor IL1-RI to
amplify IL-1-induced responses, allows site- and signal-
speciﬁc blocking of inﬂammatory responses, resulting in
reductions of plaque development and increased plaque
stability.
TRANSLATIONAL OUTLOOK: Antibody blocking of
TILRR function reduces development of atherosclerosis in
animal models to the same degree as obtained by
blocking IL-1RI expression and function, but does not
induce the side effects observed after targeting the
signaling receptor. Development of speciﬁc antibodies for
distinct blocking of TILRR-induced signal ampliﬁcation
could provide a mechanism for selective targeting of in-
ﬂammatory responses in a range of conditions. Future
preclinical and clinical trials may demonstrate transla-
tional prospects of an anti-TILRR therapy in treatment of
cardiovascular disease.
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